Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) EPS (Basic) (2020 - 2026)

Immuneering's EPS (Basic) history spans 7 years, with the latest figure at -$0.21 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 50.0% to -$0.21 in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.06, a 46.19% increase, with the full-year FY2025 number at -$1.27, up 37.75% from a year prior.
  • EPS (Basic) came in at -$0.21 for Q1 2026, down from -$0.07 in the prior quarter.
  • The five-year high for EPS (Basic) was -$0.07 in Q4 2025, with the low at -$0.59 in Q4 2024.
  • Historically, EPS (Basic) has averaged -$0.43 across 5 years, with a median of -$0.47 in 2024.
  • Biggest five-year swings in EPS (Basic): tumbled 900.0% in 2022 and later skyrocketed 88.14% in 2025.
  • Year by year, EPS (Basic) stood at -$0.5 in 2022, then fell by 4.0% to -$0.52 in 2023, then fell by 13.46% to -$0.59 in 2024, then soared by 88.14% to -$0.07 in 2025, then crashed by 200.0% to -$0.21 in 2026.
  • Business Quant data shows EPS (Basic) for IMRX at -$0.21 in Q1 2026, -$0.07 in Q4 2025, and -$0.38 in Q3 2025.